Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate.
Glycosaminoglycans (GAGs) are potent inhibitors of calcium oxalate growth and aggregation. The synthetic GAG pentosan polysulphate (PPS) was used in the treatment of patients with renal calcium stone disease. Altogether, 121 patients were included in an open trial over a 3-year-period. The average stone episode rate and the stone operation rate were no different during treatment and in the pretreatment period. Altogether 48% of the patients were entirely stone-free during follow-up, whereas 29/56 patients who continued to form stones reported smaller stones that were more easily passed. It is concluded that there may be a role for PPS in the treatment of recurrent renal calcium stone disease, but a controlled study may be needed.
Fellström
B
B
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Backman
U
U
Danielson
B
B
Wikström
B
B
D002118:Calcium / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007669:Kidney Calculi / Q000737:chemistry / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010426:Pentosan Sulfuric Polyester / Q000627:therapeutic use*; D013997:Time Factors
D010426:Pentosan Sulfuric Polyester; D002118:Calcium